Redcare Phamacy Unsp/Adr (SAEYY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and a very warm welcome also to everybody from my side. Before we start with the presentation, I would like to welcome our new CFO, Hendrik, to this round. We are happy to have Hendrik with us in the management team to further scale Redcarpharmacy. Welcome, Hendrik. Thank you. Happy to be here. Okay, let's look into the agenda of today. So first of all, we would like to start with the highlights of 2025. followed up by the financial performance 2025, an update on strategy, and then later, an update on guidance. So let's start with the highlights of 2025. The first three highlights are focused on Rx. 2025 has been a very successful year for RedCare on Rx. We almost doubled our Rx revenues in Germany, reaching 503 million euros. If we look into the relevant competition, our share of 67% demonstrates our clear market leadership position. From a group perspective, RX revenues are now exceeding €1 billion, more than 33% of total sales. The RX bonus for EE1 reformed pharmacies was confirmed not only at the ECJ again, but for the first time in history also at the highest German federal court. As a consequence, we introduced a new RxBone scheme in Q4, which supported the strong growth in Q4 of last year. In 2025, including the beginning of 2026, digital healthcare in Germany experienced a major step forward. The specs for a new and more comprehensive identification technology, POP, have been released for local but also for remote use cases. For online pharmacies this will massively increase and improve the redemption options. Customers using EGK card will no longer need SMS verification as an additional step in the order process and on top the digital health ID can be used to redeem Rx at online pharmacies. Please also keep in mind that at the beginning of 2027 the EU ...